SCHEMBL2647028

SCHEMBL2647028

O=C(O)c1ccc(CNc2ccc(C3CCCCC3)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HAO1 Q9UJM8 1/20 0.52
HDAC8 Q9BY41 2/20 0.50
HDAC6 Q9UBN7 2/20 0.50
HDAC3 O15379 1/20 0.50
HDAC11 Q96DB2 1/20 0.50
DEGS1 O15121 1/20 0.50
HTR2C P28335 1/20 0.48
HTR2B P41595 1/20 0.48
HDAC1 Q13547 1/20 0.48
KDM4C Q9H3R0 1/20 0.47
MITF O75030 1/20 0.47
KLF5 Q13887 1/20 0.47
KMT2A Q03164 2/20 0.47
KDR P35968 1/20 0.47
KMO O15229 1/20 0.46
HSD11B1 P28845 1/20 0.46
ALDH1A1 P00352 2/20 0.45
POLB P06746 2/20 0.45
MEN1 O00255 1/20 0.45
FFAR1 O14842 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2654385 0.85 CA1 (0.63) HAO1HDAC8HDAC6HDAC3HDAC11
SCHEMBL2647011 0.85 CA1 (0.63) HAO1HDAC8HDAC6HDAC3HDAC11
SCHEMBL28369685 0.83 HAO1 (0.59) HAO1HDAC8HDAC6HDAC3HDAC11
SCHEMBL2663337 0.83 GCGR (0.55) HAO1HDAC8HDAC6HDAC3HDAC11
SCHEMBL2666401 0.83 GCGR (0.55) HAO1HDAC8HDAC6HDAC3HDAC11
SCHEMBL11511592 0.82 DEGS1 (0.55) DEGS1HTR2CHTR2BKMT2AKDR
SCHEMBL16767423 0.82 RAB9A (0.61) KMT2AALDH1A1POLBMEN1HPGD
SCHEMBL11514495 0.82 MEN1 (0.47) HTR2CHTR2BKMT2AKDRALDH1A1
SCHEMBL22816011 0.82 HTT (0.51) KDRALDH1A1FFAR1CA1CA2
SCHEMBL22453749 0.82 HDAC8 (0.57) HAO1HDAC8HDAC6HDAC3HDAC11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6953812-B2 Glucagon antagonists/inverse agonists NOVO NORDISK, INC. (DK) 2005-10-11 US disclosed
US-20040024045-A1 Glucagon antagonists/inverse agonists PFIZER INC 2004-02-05 US disclosed
CN-1437581-A Glucagon antagonists/inverse agonists NOVO NORDISK AS (DK) 2003-08-20 CN disclosed
US-6562807-B2 For prophylaxis and therapy of hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity NOVO NORDISK A/S (DK) 2003-05-13 US disclosed
EP-1296942-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS Novo Nordisk A/S (DK) 2003-04-02 EP disclosed
US-20020143186-A1 Glucagon antagonists/inverse agonists PFIZER INC 2002-10-03 US disclosed
WO-2002000612-A1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK A/S (DK) 2002-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040024045-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR HAO1 2022/4885HDAC8 2908/4885HDAC6 3599/4885
US-20020143186-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR HAO1 2022/4885HDAC8 2908/4885HDAC6 3599/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.